Prosensa to Present at J.P. Morgan Healthcare Conference
JPMorgan Healthcare Conference 2013
LEIDEN, The Netherlands -- January 3, 2013
Prosensa, the private Dutch biopharmaceutical company focusing on
RNA-modulating therapeutics for rare diseases with high unmet need, today
announced that Hans Schikan, Chief Executive Officer, will be presenting at
the 31^st Annual J.P. Morgan Healthcare Conference in San Francisco.
Prosensa’s presentation is scheduled at the Westin St. Francis on Union Square
at 4.30pm PST on Monday, January 7, 2013 and will provide a corporate update
to the investment community. Prosensa’s lead compound (drisapersen), being
developed by GlaxoSmithKline, is currently in late-stage phase III clinical
trials for Duchenne muscular dystrophy.
Notes to editors:
Prosensa is an innovative Dutch biopharmaceutical company focused on the
discovery, development and commercialization of RNA-modulating therapeutics
correcting gene expression in diseases with significant unmet need, in
particular neuromuscular disorders. Prosensa’s current focus is on developing
treatments for Duchenne muscular dystrophy (DMD), Myotonic Dystrophy and
Huntington’s disease. In 2009 Prosensa entered into a strategic alliance for
part of its DMD exon skipping program with GlaxoSmithKline. Prosensa’s lead
compound (drisapersen), being developed by GSK, is currently in late-stage
phase III clinical trials. Prosensa is a privately held biopharmaceutical
company, backed by a consortium of Abingworth, Gimv, Idinvest Partners, Life
Sciences Partners, MedSciences Capital and New Enterprise Associates. For more
information, please visit www.prosensa.com.
Prosensa won the 2012 Emerging Star Award at the European Mediscience Awards
and was listed as a Fierce 15 Biotech Company.
Luc Dochez +31 71 332 2085
Hans Schikan +31 71 332 2100
College Hill Life Sciences
Melanie Toyne-Sewell / Anastasios Koutsos / Henry Stanley
+44 20 7457 2020
Rebecca Skye Dietrich (US enquiries)
+1 857 241 0795
Press spacebar to pause and continue. Press esc to stop.